Browse Items (1 total)

Tags: *Pancreatic cancer

Sort by:

The use of eculizumab in gemcitabine induced thrombotic microangiopathy.

BACKGROUND: Thrombotic microangiopathy (TMA) secondary to gemcitabine therapy (GiTMA) is a very rare pathology that carries a poor prognosis, with nearly half of the cases progressing to end stage renal disease. GiTMA is most commonly associated with…

Tags: *Gemcitabine, *Hemolytic uremic syndrome, *Pancreatic cancer, *Renal failure, *Thrombotic microangiopathy, 2018, Antibodies, Antimetabolites, Antineoplastic – Adverse Effects, Antineoplastic/*adverse effects, BMC nephrology, Das Abhijit, Deoxycytidine, Deoxycytidine – Adverse Effects, Deoxycytidine/adverse effects/*analogs & derivatives, Department of Internal Medicine, Female, Gupta Mohit, Humanized/*therapeutic use, Humans, Krishnappa Vinod, Middle Age, Middle Aged, Monoclonal, Monoclonal – Therapeutic Use, NEOMED College of Graduate Studies Student, NEOMED College of Medicine, Novak Robert, Raina Rupesh, Scales, Shah Haikoo, Tanphaichitr Natthavat, Thrombocytopenia – Chemically Induced, Thrombocytopenia – Diagnosis, Thrombocytopenia – Drug Therapy, Thrombotic Microangiopathies/*chemically induced/diagnosis/*drug therapy

Output Formats

atom, dcmes-xml, json, omeka-xml, rss2